Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally.
It offers services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications.
In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies.
The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022.
Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
| Country | United States |
| Founded | 1986 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 406 |
| CEO | Paul Josephs |
Contact Details
Address: 3515 Lyman Boulevard Chaska, Minnesota 55318 United States | |
| Phone | 952 368 4300 |
| Website | lifecore.com |
Stock Details
| Ticker Symbol | LFCR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001005286 |
| CUSIP Number | 514766104 |
| ISIN Number | US5147661046 |
| Employer ID | 94-3025618 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Josephs | President, Chief Executive Officer and Director |
| Ryan D. Lake CPA | Executive Vice President and Chief Financial Officer |
| Thomas D. Salus | Chief Legal and Administration Officer and Corporate Secretary |
| Thomas Guldager | Senior Vice President of Operations |
| Aaron Perlitsh | Director of Internal Audit and Chief Compliance Officer |
| Jackie Q. Klecker | Executive Vice President of Quality and Development Services |
| Mark DaFonseca | Chief Commercial Officer |
| Parker K. Javid | Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 16, 2026 | 10-KT | Filing |
| Mar 16, 2026 | 8-K | Current Report |
| Mar 5, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13G | Filing |
| Jan 16, 2026 | 8-K | Current Report |
| Nov 17, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Oct 31, 2025 | 8-K | Current Report |
| Oct 17, 2025 | SCHEDULE 13G/A | Filing |